Defining information fractions in group sequential clinical trials with multiple endpoints
The group sequential design has been well understood and widely applied in designs of late giantmouse tribeca phase clinical trial to enable potentially early stopping for efficacy or futility.The information fraction (IF) is one of the key elements to determine the decision boundary at the interim analyses.The family-wise error rate (FWER) control